In a 2018 single-institution randomized phase II trial by Iyengar et al., patients with NSCLC who demonstrated stable disease after 4–6 cycles of platinum-based chemotherapy, were negative for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusion genes, and had up to five metastatic lesions (with no more than three in the lungs or liver) were enrolled [12]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.